Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.
about
Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the ShipAnticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsCurrent and emerging techniques for antibiotic susceptibility testsImpact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report.Clinical laboratory detection of carbapenem-resistant and carbapenemase-producing Enterobacteriaceae.Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam.The Susceptibility Testing Manufacturers Association Presents an Opinion for the Delay of Current Susceptibility Tests.New Antimicrobial Agents … but No Susceptibility Tests!Carbapenem-resistant Enterobacteriaceae (CRE) detection practices in California: What are we missing?Reply to Kircher et al.Analysis of Potential β-Lactam Surrogates to Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.Assessment of Ceftazidime-Avibactam 30/20 μg Disk Content Versus MIC Results When Tested against Enterobacteriaceae and Pseudomonas aeruginosa.The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care.The Point of Antimicrobial Susceptibility Testing Is to Inform Antimicrobial Prescribing.
P2860
Q28068503-F3E7FF46-A795-470B-91E0-620169691559Q33732524-0AFD07DE-8EE3-434A-A91B-39C275EE94F2Q33820956-24F92FAF-BBD7-4689-B92D-7F94400A9C1CQ37363425-C0EDAC48-7E2D-46CF-BFF0-EB6502FDC2E0Q38641810-F4794580-3D8A-4911-96DD-B1D64AB1D6AEQ40635231-1629C480-D7BB-4B69-BE9F-D55EDE621764Q42004132-8BA2960E-7F36-4F53-A976-FFA3A3BC8822Q42331365-BF0893E2-A16A-4617-898D-B3E9AD48F872Q45985435-BDE01D6E-399C-4D43-B58F-9B205810E25AQ46203940-CADB75D3-2487-4953-A425-52AD4AADD6FBQ46330538-26004E2C-80BF-4D69-8D10-B94D8292FF6FQ46518087-B84680A3-F6D8-47A9-882A-57BEBCDCD802Q50048535-1155BCA5-B31E-4C1B-99B4-6F75562C6001Q50048562-F61AE780-9A03-4B9A-B693-25A9AE6C30CCQ52644115-73BAC004-0FE3-4EA8-A049-8C952848D767Q53108123-FFC262B8-EEA1-4BF3-A579-0C21A47A033AQ54497201-C6E753C5-5BD7-4BA6-9D01-4A65332FF640
P2860
Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@en
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@nl
type
label
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@en
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@nl
prefLabel
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@en
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@nl
P2860
P356
P1476
Emerging Resistance, New Antim ...... rrent US Regulatory Landscape.
@en
P2093
J A Hindler
R M Humphries
P2860
P356
10.1093/CID/CIW201
P407
P577
2016-03-29T00:00:00Z